Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney

作     者：Qiaohui Chen Yayun Nan Yuqi Yang Zuoxiu Xiao Min Liu Jia Huang Yuting Xiang Xingyu Long Tianjiao Zhao Xiaoyuan Wang Qiong Huang Kelong Ai 

作者机构：Xiangya School of Pharmaceutical SciencesCentral South UniversityChangshaHunan410078PR China Hunan Provincial Key Laboratory of Cardiovascular ResearchXiangya School of Pharmaceutical SciencesCentral South UniversityChangsha410078PR China Department of PharmacyXiangya HospitalCentral South UniversityChangshaHunan410008PR China National Clinical Research Center for Geriatric DisordersXiangya HospitalCentral South UniversityChangshaHunan410008PR China Geriatric Medical CenterPeople’s Hospital of Ningxia Hui Autonomous RegionYinchuanNingxia750002PR China 

出 版 物：《Bioactive Materials》 (生物活性材料（英文）)

年 卷 期：2023年第22卷第4期

页      面：141-167页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

基　　金：This work was supported by the National Natural Science Foundation of China,China(No.81974508,21974134) the Hunan Science Fund for Distinguished Young Scholar(No.2021JJ10067) Innovation-Driven Project of Central South University(No.202045005),Hunan Provincial Natural Science Foundation of China(No.2021JJ31066) Key Research Project of Ningxia Hui Autonomous Region in 2021(Major Project)(No.2021BEG01001) The Key Program of Ningxia Hui Autonomous Region Natural Science Foundation of China(No.2022JJ21059) 

主　　题：Reactive oxygen and nitrogen species Acute kidney injury Nanomaterials Antioxidant therapy Renal physiology 

摘      要：Currently,there are no clinical drugs available to treat acute kidney injury(AKI).Given the high prevalence and high mortality rate of AKI,the development of drugs to effectively treat AKI is a huge unmet medical need and a research *** existing evidence fully demonstrates that reactive oxygen and nitrogen species(RONS)burst at the AKI site is a major contributor to AKI progression,the heterogeneity,complexity,and unique physiological structure of the kidney make most antioxidant and anti-inflammatory small molecule drugs ineffective because of the lack of kidney targeting and side ***,nanodrugs with intrinsic kidney targeting through the control of size,shape,and surface properties have opened exciting prospects for the treatment of *** antioxidant nanodrugs have emerged to address the limitations of current AKI *** this review,we systematically summarized for the first time about the emerging nanodrugs that exploit the pathological and physiological features of the kidney to overcome the limitations of traditional small-molecule drugs to achieve high AKI ***,we analyzed the pathological structural characteristics of AKI and the main pathological mechanism of AKI:hypoxia,harmful substance accumulation-induced RONS burst at the renal site despite the multifactorial initiation and heterogeneity of ***,we introduced the strategies used to improve renal targeting and reviewed advances of nanodrugs for AKI:nano-RONS-sacrificial agents,antioxidant nanozymes,and nanocarriers for antioxidants and anti-inflammatory *** nanodrugs have demonstrated excellent therapeutic effects,such as greatly reducing oxidative stress damage,restoring renal function,and low side ***,we discussed the challenges and future directions for translating nanodrugs into clinical AKI treatment.